Category: Blood Diseases
Global Blood Diseases
-
The 2025-2030 World Outlook for Rare Hematology Plasma-Derived Factors
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Haemoglobinopathies
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Hemoglobinopathies
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Plasma Fractionation of Intravenous Immunoglobulins
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Monocyte Activation Test Kits
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Blood Cancers
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Bleeding Disorders Treatments
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Sickle Cell Disease Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Sickle Cell Disease Hemoglobinopathies
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Indication (Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032
... Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032 The global biosimilar market size reached US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 164.5 Billion by 2032, exhibiting ... Read More
-
Global Anemia Therapeutics Market Growth (Status and Outlook) 2024-2030
... market, the Anemia Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Anemia Therapeutics ... Read More
-
Global Alpha Thalassemia Market Growth (Status and Outlook) 2024-2030
... market, the Alpha Thalassemia is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Alpha Thalassemia ... Read More
-
Global Acquired Aplastic Anemia Market Growth (Status and Outlook) 2024-2030
... in downstream market, the Acquired Aplastic Anemia is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the ... Read More
-
Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2024
... Deficiency) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A (Factor VIII Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries ... Read More
-
Global Rare Hemophilia Factors Market Growth (Status and Outlook) 2024-2030
... demand in downstream market, the Rare Hemophilia Factors is forecast to a readjusted size of US$ 242.3 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential ... Read More
-
Global Thalassemia Market Growth (Status and Outlook) 2024-2030
... the Thalassemia is forecast to a readjusted size of US$ 5324.4 million by 2030 with a CAGR of 8.8% during review period. The research report highlights the growth potential of the global Thalassemia market. Thalassemia ... Read More
-
Global Renal Anemia Therapeutics Market Growth (Status and Outlook) 2024-2030
... in downstream market, the Renal Anemia Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the ... Read More
-
Chemotherapy-Induced Anemia Global Market Report 2024
... Surgical Centers; Multispecialty Clinics; Cancer Research Centers; Cancer Rehabilitation CentersCovering: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG Chemotherapy-Induced Anemia Global Market Report 2024 from The Business Research ... Read More
-
Thalassemia Drugs Global Market Report 2024
... Inc.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.; Fresenius Kabi AG Thalassemia Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need ... Read More
-
2024 Global Forecast for Hemophilia Treatment Market (2025-2030 Outlook)-High Tech & Emerging Markets Report
... product or service category is within the NAICS Chemical Manufacturing industry. The product or service category is within the NAICS Chemical Manufacturing industry. The global market is expected to increase from USD xx billion in ... Read More
-
PEGylated Proteins Market Report by Product (Consumables, Services), Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VII, and Others), Application (Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, and Others), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes), and Region 2024-2032
... End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes), and Region 2024-2032 The global PEGylated proteins market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market ... Read More
-
Bone Marrow Transplantation Market by Type (Allogeneic Transplant, Autologous Transplant), Treatment Type (Aplastic Anemia, Leukemia, Lymphoma), End-User - Global Forecast 2024-2030
... and expected to reach USD 17.62 billion in 2024, at a CAGR 8.74% to reach USD 29.26 billion by 2030. Global Bone Marrow Transplantation Market FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in ... Read More
-
Chemotherapy Induced Anemia Market by Range Of Anemia (Life-Threatening Anemia, Mild Anemia, Moderate Anemia), Treatment (Erythropoiesis-Stimulating Agents, Iron Supplementation, RBC Transfusions), Drug, End-User - Global Forecast 2024-2030
... at USD 2.51 billion in 2023 and expected to reach USD 2.70 billion in 2024, at a CAGR 7.36% to reach USD 4.14 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal ... Read More
-
Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2024-2030
... 2023 and expected to reach USD 2.79 billion in 2024, at a CAGR 33.02% to reach USD 19.46 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Hemoglobinopathies Market. ... Read More
-
Erythropoietin Stimulating Agents Market by Type (Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta), Application (Anemia, Antiretroviral Treatment, Cancer Chemotherapy) - Global Forecast 2024-2030
... 2023 and expected to reach USD 10.32 billion in 2024, at a CAGR 5.64% to reach USD 14.45 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Erythropoietin Stimulating ... Read More
Research Assistance
